Improve Yield, Purity, and Scalability in Lentiviral Vector Production
Available On Demand, 45 minutes
As CAR-T therapies expand from ex vivo to in vivo applications, lentiviral vector manufacturing must meet higher expectations for yield, impurity clearance, scalability, and regulatory compliance.
In this on-demand webinar, our expert, Brian Tomkowicz, PhD, Vice-President, Head of R&D and Virology Fellow at SK pharmteco, discusses how our company has developed a robust, industrialized downstream platform that supports ex vivo CAR-T manufacturing while delivering the quality, consistency, and process control required for in vivo therapeutic use.
What You’ll Learn
- How LVV design and quality requirements differ between ex vivo and in vivo CAR-T applications
- Scalable and cost-efficient approaches for industrialized LVV manufacturing
- The impact of evolving regulatory and quality expectations on modern LVV platform development
View the on-demand webinar now.
Presenter: Brian Tomkowicz, PhD
Vice-President, Head of R&D and Virology Fellow
SK pharmteco